Happy New Year!
Event Announcements &
Most Viewed 2021 News
2021 was again quite a year with the challenges presented by the COVID-19 pandemic. Biotech Networks launched its first US east coast hub in Boston/Cambridge as well as more virtual events, including career fairs. Watch for the announcement for two new geographic hubs launching in January, with more to come throughout 2022. Thanks to all who attended events and supported our 2021 activities, we wish you a happy and prosperous 2022.
With new variants of COVID-19 that continue to emerge, we will continue meeting virtually, and we continue to innovate in empowering you to connect easily and safely online within and between our hubs. Join us January 27th for a combined speed networking and diversity and inclusion event, and again February 10th for our first bicoastal career fair. Sponsorships for each event are available, contact us soon to jump start your companies’ 2022 lead generation and recruiting efforts.
You’ve helped us determine the top news by clicking, reading, and sharing the articles on our websites, see which had the most views in 2021 for each Biotech Networks hub below. Do our results accurately represent the most popular 2021 biotech news stories? No, there are many variables that may skew one story over another. However, we think you’ll find the results below interesting.
Several news outlets provide our news feeds, please follow and subscribe to them as well. To keep current with weekly Biotech Networks trending news, click here to get BN Briefs delivered to your inbox every Friday.
BCBN 2021 (June-Dec.) Most Viewed News*
- New face mask prototype can detect Covid-19 infection
- Scoop: Bob Nelsen is building a Really Big Neuroscience Company
- VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
- LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
- Gemini Therapeutics to Participate in Upcoming Investor Conferences
- Science pioneer, pharma research chief, global health advocate and biotech entrepreneur Tadataka ‘Tachi’ Yamada has died
- Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021
- With $100M, startup to bring Lilly-licensed drug into trials
- EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD
- Exclusive: Big-name academics and investors are quietly preparing a slate of new (epi)genome editing companies
All BCBN News
SFBN 2021 Most Viewed News
- After 3 deaths rock the field, gene therapy researchers contemplate AAV’s future
- Scoop: Bob Nelsen is building a Really Big Neuroscience Company
- Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
- Asher Biotherapeutics joins search for a better IL-2 sans the toxicities
- Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died
- Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
- Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors
- Humanigen Announces Release of Abstracts at ASH
- Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting
- How David Liu turned Botox into his next drug discovery platform — a molecular axe that can maybe shred Tau, RAS and a host of the worst disease-causing proteins
All SFBN News
SDBN 2021 Most Viewed News
- ‘Feel Good’ Brain Messenger Can Be Willfully Controlled, New Study Reveals
- UCSD fears mass COVID surge could hit San Diego around New Year’s. Here’s why
- Philanthropic donations to Salk Institute exceed record-breaking $100M in FY21
- Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer
- Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento’s Portfolio of COVID-19 Products in Mexico and Parts of Latin America
- ‘Disappointing’ ViaCyte data raise questions about future of company’s attempted diabetes cure
- FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
- Boston, the Bay Area and San Diego dominate the life sciences real estate market. Where to next?
- German drug giant Bayer plants flag in San Diego with $2B biotech acquisition
- Chicago firms to pay $576M to build sprawling life science campus in Sorrento Mesa
All SDBN News
LABN 2021 Most Viewed News
- Nasdaq rings in its first biotech IPOs of 2021: a CAR-T specialist from China, a cancer portfolio play, and a SPAC
- A veteran oncology startup crew is making a very serious bet that they’ve found the key to unlocking the promise of oncolytic viruses
- Amgen halts a PhI for FLT3 BiTE while resuming dosing on another
- Henry Skinner buys time in the fight against antimicrobial resistance; Vertex’s Michael Parini becomes president and COO at Freeline while CFO Brian Silver plans his exit
- The U.S. is more racially diverse than ever. Will people of color unify politically?
- AirQuality Technology (AQT), One of the Largest Air Purification Solutions Providers, Unveils Indoor Air Purifiers Proven to Kill 99.99% of COVID-19 Virus for North America
- AstraZeneca’s MCL-1 cancer drug put on hold after flagging a safety issue — 2 years after Amgen axed rival drug
- AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation
- Amgen showcases its last big round of promising KRAS G12C data for sotorasib. Next up: A likely marketing campaign for a breakthrough therapy
- Scoop: Amgen recruits renowned cancer drug investigator Jean-Charles Soria to lead a growing pipeline play
Be the first to comment